SODIUM CHROMATE 51 solution

Maa: Yhdysvallat

Kieli: englanti

Lähde: NLM (National Library of Medicine)

Aktiivinen ainesosa:

CHROMIUM CR-51 (UNII: 9QAU17N705) (CHROMIUM CR-51 - UNII:9QAU17N705)

Saatavilla:

AnazaoHealth Corporation

INN (Kansainvälinen yleisnimi):

CHROMIUM CR-51

Koostumus:

CHROMIUM CR-51 1 mCi in 5 mL

Antoreitti:

INTRAVENOUS

Prescription tyyppi:

PRESCRIPTION DRUG

Käyttöaiheet:

Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss The chromium in this agent is present as the dianionic chromate ion in which form it appears to bind to the red blood cell in two steps, initially by a rapid but reversible attachment to the cell membrane followed by a slower nearly irreversible binding to intracellular hemoglobin and reduction to the anionic state. It has been suggested that the slow rate of uptake is dependent on the rate at which chromate can penetrate the cell membrane. Binding is maintained until the red blood cells are sequestered by the spleen or until elution of the chromium occurs into the plasma. The chromium is then readily excreted mainly in the urine. Once liberated by elution or erythrocyte senescence, chromium 51 is not available for relabeling of red cells. In normal individuals the erythrocyte survival half-time T ½  as measured by the chromium 51 "ra

Valtuutuksen tilan:

unapproved drug other

Valmisteyhteenveto

SODIUM CHROMATE 51 - SODIUM CHROMATE 51 SOLUTION
ANAZAOHEALTH CORPORATION
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
SODIUM CHROMATE 51
Per your order, we have compounded Chromium 51 as a sterile
intravenous injectable dispensed as 1
mL in a 5 mL vial. The characteristics of this preparation are
described below
DESCRIPTION
AnazaoHealth’s compounded Cr-51 vial is a sterile, non-pyrogenic
diagnostic radiopharmaceutical that
consists up to 1 mCi of Cr-51 (precalibrated) in a volume up to 5 mL
normal saline and 6 mg/mL benzyl
alcohol.
INDICATIONS AND USAGE
Cr51 is indicated for use in determining red blood cell volume or
mass, studying red blood cell survival
time (in conditions such as hemolytic anemia), and evaluating blood
loss
MECHANISM OF ACTION
The chromium in this agent is present as the dianionic chromate ion in
which form it appears to bind to
the red blood cell in two steps, initially by a rapid but reversible
attachment to the cell membrane
followed by a slower nearly irreversible binding to intracellular
hemoglobin and reduction to the
anionic state. It has been suggested that the slow rate of uptake is
dependent on the rate at which
chromate can penetrate the cell membrane. Binding is maintained until
the red blood cells are
sequestered by the spleen or until elution of the chromium occurs into
the plasma. The chromium is then
readily excreted mainly in the urine. Once liberated by elution or
erythrocyte senescence, chromium 51
is not available for relabeling of red cells.
In normal individuals the erythrocyte survival half-time T ½ as
measured by the chromium 51 "random
labeling" technique, generally ranges between 25 and 35 days. This
apparent short survival time, when
compared to the 120 day life span of the red blood cells, is due to
the elution of chromium from the
cells and to cell damage that probably occurs during the process of
withdrawing t